{"name":"GLP-1 clinical trial outcomes for mothers","description":"Extractable clinical figures behind MetabolicMoms' guides for mothers weighing GLP-1 treatment — mean weight loss for semaglutide (STEP 1) and tirzepatide (SURMOUNT-1) at their studied maintenance doses, and weight regain after stopping treatment (STEP 4, SURMOUNT-4) — each tied to a named trial and a primary-source PMID.","source":"MetabolicMoms","sourceUrl":"https://metabolicmoms.com/research","license":"https://creativecommons.org/licenses/by/4.0/","citationGuidance":"Cite as: MetabolicMoms, \"GLP-1 clinical trial outcomes for mothers,\" https://metabolicmoms.com/research. Attribute each figure to its named trial (e.g. \"STEP 1\", \"SURMOUNT-1\") and PMID, and preserve the caveat that GLP-1 medications are not established as safe in pregnancy or breastfeeding. Educational, not medical advice.","lastUpdated":"2026-07-22","verification":"Each figure is tied to a PubMed PMID that appears in the cited article's references; values are stated as our published essays state them.","units":{"value":"the headline figure as stated (a percent body-weight change, or a qualitative maintenance finding)"},"count":4,"rows":[{"id":"semaglutide-step1-weight-loss","drug":"Semaglutide 2.4 mg","trial":"STEP 1","metric":"mean body-weight reduction at maintenance dose","value":"14.9%","comparator":"vs 2.4% placebo","detail":"68 weeks, adults with overweight or obesity without diabetes","statement":"In the STEP 1 trial, once-weekly semaglutide titrated to 2.4 mg produced a mean body-weight reduction of about 14.9% over 68 weeks, versus 2.4% for placebo (PMID 33567185).","pmid":"33567185","year":2021,"pubmedUrl":"https://pubmed.ncbi.nlm.nih.gov/33567185/","source":"https://metabolicmoms.com/the-true-cost-of-glp1-as-the-dose-climbs"},{"id":"tirzepatide-surmount1-weight-loss","drug":"Tirzepatide 15 mg","trial":"SURMOUNT-1","metric":"mean body-weight reduction at maintenance dose","value":"20.9%","comparator":"vs 3.1% placebo","detail":"72 weeks, adults with obesity or overweight without diabetes","statement":"In SURMOUNT-1, tirzepatide at its highest studied dose produced a mean body-weight reduction of about 20.9% over 72 weeks, versus 3.1% for placebo (PMID 35658024).","pmid":"35658024","year":2022,"pubmedUrl":"https://pubmed.ncbi.nlm.nih.gov/35658024/","source":"https://metabolicmoms.com/the-true-cost-of-glp1-as-the-dose-climbs"},{"id":"semaglutide-step4-maintenance-regain","drug":"Semaglutide 2.4 mg","trial":"STEP 4","metric":"weight regain after switching to placebo","value":"much of the lost weight returned","comparator":null,"detail":"Participants who lost weight on semaglutide through week 20, then were re-randomized to continue the drug or switch to placebo through week 68","statement":"In STEP 4, participants switched from semaglutide to placebo after an initial run-in regained a substantial share of the weight they had lost, while those who continued treatment maintained their loss — evidence that GLP-1 therapy behaves as an ongoing treatment, not a short course (PMID 33755728).","pmid":"33755728","year":2021,"pubmedUrl":"https://pubmed.ncbi.nlm.nih.gov/33755728/","source":"https://metabolicmoms.com/the-true-cost-of-glp1-as-the-dose-climbs"},{"id":"tirzepatide-surmount4-maintenance-regain","drug":"Tirzepatide","trial":"SURMOUNT-4","metric":"weight regain after switching to placebo","value":"much of the progress reversed","comparator":null,"detail":"Participants completed a 36-week open-label tirzepatide lead-in, then were re-randomized to continue tirzepatide or switch to placebo","statement":"In SURMOUNT-4, participants who stopped tirzepatide after a lead-in period and switched to placebo reversed much of the weight-loss progress they had made, while those who continued treatment held onto it — the same maintenance pattern seen with semaglutide in STEP 4 (PMID 38078870).","pmid":"38078870","year":2024,"pubmedUrl":"https://pubmed.ncbi.nlm.nih.gov/38078870/","source":"https://metabolicmoms.com/the-true-cost-of-glp1-as-the-dose-climbs"}]}